AFQ056
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mild Moderate
Conditions
Mild Moderate, or Severe Renal Impairment
Trial Timeline
Jan 1, 2011 → Aug 1, 2011
NCT ID
NCT01442259About AFQ056
AFQ056 is a phase 1 stage product being developed by Novartis for Mild Moderate. The current trial status is completed. This product is registered under clinical trial identifier NCT01442259. Target conditions include Mild Moderate, or Severe Renal Impairment.
What happened to similar drugs?
8 of 17 similar drugs in Mild Moderate were approved
Approved (8) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01491932 | Phase 2 | Completed |
| NCT01482143 | Phase 1 | Completed |
| NCT01433354 | Phase 2/3 | Terminated |
| NCT01348087 | Phase 2 | Terminated |
| NCT01456663 | Phase 1 | Completed |
| NCT01442259 | Phase 1 | Completed |
| NCT01173731 | Phase 2 | Completed |
| NCT00414856 | Phase 1 | Completed |
Competing Products
20 competing products in Mild Moderate